The recently-approved oral antiviral molnupiravir will be the first to be investigated in a UK-wide trial of new treatments for COVID-19 in patients at higher risk of complications from the disease. The Platform Adaptive trial of Novel Antivirals for Early Treatment of COVID-19 In the Community (PANORAMIC) aims to rapidly evaluate several antiviral treatments that could help clinically vulnerable people diagnosed with COVID-19 recover sooner and prevent them having to attend hospital.
展开▼
